MORF
Morphic Holding, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website morphictx.com
- Employees(FY) 115
- ISIN US61775R1059
Performance
+0.34%
1W
+4.96%
1M
-22.43%
3M
+26.48%
6M
+1.21%
YTD
-48.24%
1Y
Profile
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Investment Analysis Report: MORF
Overview
In this investment analysis report, we will delve into a comprehensive evaluation of MORF, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operatin...
Technical Analysis of MORF 2024-05-10
Overview:
In analyzing the technical indicators for MORF stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible future stock price movement. By examining these key indicators, we aim to offer valuable insights and predictions for the upcoming tradin...
Recent News & Updates
- 2024-05-09 16:05
- 2024-05-09 04:05
- 2024-05-01 07:32
- 2024-04-25 08:37
- 2024-04-25 07:00
- 2024-04-25 01:53
MORF Stock Earnings: Morphic Holding Beats EPS for Q1 2024(Investorplace)
- 2024-04-24 19:00
- 2024-04-24 12:00
- 2024-04-24 00:00
- 2024-03-21 09:43
Morphic Holding Insiders Placed Bullish Bets Worth US$47.3m(Simply Wall St.)
- 2024-03-20 01:57
- 2024-03-19 08:00
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer(GlobeNewswire)
- 2024-03-18 20:00
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer(Globenewswire)
- 2024-03-05 16:05
Morphic to Participate in March Investor Conferences(GlobeNewswire)
- 2024-03-05 03:05
Morphic to Participate in March Investor Conferences(Globenewswire)
- 2024-02-26 09:55
- 2024-02-25 20:55
- 2024-02-22 07:00
- 2024-02-21 18:00
- 2024-02-08 09:55
- 2024-02-07 20:55
- 2024-01-18 07:04
- 2024-01-05 09:55
- 2024-01-03 16:05
- 2024-01-03 03:05
- 2023-12-20 09:55
- 2023-12-01 09:55
- 2023-12-01 02:59
- 2023-11-23 05:45
- 2023-11-15 09:55
Page 1 of 5
previousnext